Changes in eotaxin-3 and pulmonary and activation-regulated chemokine levels in patients after dupilumab treatment: a systematic review and meta-analysis

INTRODUCTION: Dupilumab is approved for a variety of type 2 inflammatory diseases. Changes in chemokine levels during treatment require further analysis. AIM: We evaluated changes in eotaxin-3 and PARC levels after dupilumab treatment through a meta-analysis, aiming to provide more comprehensive res...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Leyi, Cheng, Haiyan, Zhou, Boyang, Li, Linfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2023
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646707/
https://www.ncbi.nlm.nih.gov/pubmed/38028411
http://dx.doi.org/10.5114/ada.2023.132231

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646707/
https://www.ncbi.nlm.nih.gov/pubmed/38028411
http://dx.doi.org/10.5114/ada.2023.132231

Ejemplares similares